Biogen (BIIB) Operating Expenses (2009 - 2026)

Biogen's Operating Expenses history runs 18 years deep, the most recent figure standing at $2.1 billion for Q1 2026.

• In Q1 2026, Operating Expenses fell 0.93% year-over-year to $2.1 billion; the TTM figure through Mar 2026 stood at $8.3 billion (up 3.11% YoY), while the FY2025 annual figure was $8.3 billion, up 7.26% from the prior year.
• Operating Expenses was $2.1 billion for Q1 2026 at Biogen, down from $2.3 billion in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $2.7 billion in Q3 2023 to a low of $1.1 billion in Q3 2022.
• Historically, Operating Expenses has averaged $2.0 billion across 5 years, with a median of $2.0 billion in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses sank 54.28% in 2022, then jumped 134.88% in 2023.
• A 5-year view of Operating Expenses shows it stood at $1.9 billion in 2022, then gained by 7.96% to $2.1 billion in 2023, then grew by 3.27% to $2.2 billion in 2024, then advanced by 7.96% to $2.3 billion in 2025, then declined by 10.08% to $2.1 billion in 2026.
• The last three Operating Expenses figures came in at $2.1 billion (Q1 2026), $2.3 billion (Q4 2025), and $2.0 billion (Q3 2025), per Business Quant data.